Design Therapeutics’ Q2 2026 10-Q highlights encouraging pharmacokinetic improvements in its lead Friedreich ataxia candidate DT-216P2 from the proprietary GeneTAC® platform. The FDA lifted a prior clinical hold in December 2025, enabling Phase 1/2 multiple ascending dose trials underway with readouts expected late 2026. The company pursues a pipeline addressing multiple nucleotide repeat expansion diseases, benefiting from small-molecule modality advantages. Despite inherent clinical development risks, Design’s strong cash position and current ratio provide runway visibility amid high R&D burn typical of this biotech sub-sector.